








Humana’s fast-growing CenterWell healthcare services business added another network of senior primary care centers with the acquisition of Florida-based MaxHealth.
HUM incurs a wider year-over-year loss in Q4 due to rising costs, weaker investment income and membership declines. Yet, revenues climb 12% on CenterWell strength.
Humana reported a $796 million fourth quarter loss as the health insurer continued to grapple with high medical costs of its Medicare Advantage health plan members.
Humana forecast annual profit below Wall Street estimates on Wednesday, as the health insurer expects a hit from lower quality ratings for its Medicare Advantage plans for older adults.
Image source: The Motley Fool.DateFeb. 5, 2026 at 4:30 p.m. ETCall participantsChief Executive Officer — Chad RobinsChief Financial Officer — Kyle PiskelChief Commercial Officer — Susan BobulskyChief Business Development and Partnerships Officer — Sharon BenzenoTakeawaysTotal company revenue -- $277 million for 2025, up 55% year over year, including 51% growth to $71.7 million in the fourth quarter.MRD revenue -- $212 million in 2025, increasing 46% with clinical clonoSEQ testing revenue up...
These are the stocks posting the largest moves in early trading.
An den US-Börsen dürften am Dienstag Technologiewerte weiter zulegen. Die Befürchtungen der Anleger mit Blick auf die Handelspolitik Washingtons rückten weiter in den Hintergrund, auch wenn Präsident Donald Trump nun die Zölle für den Import südkoreanischer Produkte erhöhen will; für etwas Erleichterung sorgt vielmehr die in Summe weiterhin recht gut verlaufende Berichtssaison der Unternehmen.
UnitedHealth hat das vierte Geschäftsquartal 2025 mit einem kräftigen Gewinneinbruch abgeschlossen. Das Ergebnis je Aktie sackte von 5,98 US-Dollar auf 2,11 US-Dollar ab und lag damit über den Analystenschätzungen ...
Healthcare stocks tumble after the Trump administration proposes to keep payments for Medicare Advantage plans roughly flat in 2027.
Major insurance stocks sank after The Wall Street Journal reported the Trump administration is proposing roughly flat rates for Medicare insurers next year, far less than W
Shares of large Medicare plan providers Humana, CVS Health and UnitedHealth Group plunged in extended trading.
Shares of insurance giants including UnitedHealth Group, Humana and CVS Health were hit hard late Monday after a report in The Wall Street Journal said the Trump
After-hours movers: Humana, UnitedHealth, CVS Health, Sanmina and more
UnitedHealth Group, Centene, Humana and Elevance face new uncertainty as Trumps Great Healthcare Plan targets premiums, drug prices and transparency.
Wells sees tougher backdrop for healthcare stocks, cuts Humana, UnitedHealth
Whether youre a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
UnitedHealth, Humana and Centene have been highlighted in this Industry Outlook article.
Humana (HUM) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates for some clues.
The health insurance giant Humana and Mark Cuban’s Cost Plus Drugs are discussing ways to partner to lower the cost of prescription drugs for U.S. employers.
Humana at Wolfe Research Conference: Strategic Medicare Insights
Humana reported third-quarter profit that beat Wall Street estimates on Wednesday, on higher premiums.
Humana posts better-than-expected third-quarter profit
PHILADELPHIA, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Avantor, Inc. (NYSE: AVTR):
Humana, Cencora and Globus Medical are poised to outshine in the September quarter, driven by strong demand, innovation and volume growth.
Humana, Cencora and Globus Medical are poised to outshine in the September quarter, driven by strong demand, innovation and volume growth.
Humana, Cencora and Globus Medical are poised to outshine in the September quarter, driven by strong demand, innovation and volume growth.
Humana, Cencora and Globus Medical are poised to outshine in the September quarter, driven by strong demand, innovation and volume growth.
Humana, Cencora and Globus Medical are poised to outshine in the September quarter, driven by strong demand, innovation and volume growth.
Humana, Cencora and Globus Medical are poised to outshine in the September quarter, driven by strong demand, innovation and volume growth.